Article Text

Download PDFPDF
Manipulation of the gut–liver axis by interruption of bile acid recirculation: an option for the treatment of sclerosing cholangitis?

Statistics from


  • MM and AG share senior authorship

  • Contributors DJ and AG created the first draft of the manuscript. All authors discussed the general outline of the manuscript; reviewed, edited and approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DJ: nothing to disclose. MM: nothing to disclose. AG advises for AbbVie, Alexion, BMS, Gilead, Intercept, Novartis, and Sequana, is on the speakers’ bureau for AbbVie, Alexion, BMS, Falk, Gilead, Intercept, Novartis and Sequana, and received research grants from Intercept and Novartis.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles